GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 28, 2004, 14:33:06 ; Search time 22 Seconds
(without alignments)
661.751 Million cell updates/sec

Title: US-10-063-567-60
Perfect score: 1431
Sequence: 1 MASLGQILFWSIISIIIILA.....SSFFAISWALLPLSPYLMLK 282

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1431	100.0	282	4	US-09-404-879A-393	Sequence 393, App
2	1431	100.0	309	4	US-09-404-879A-392	Sequence 392, App
3	246.5	17.2	316	4	US-09-910-174B-24	Sequence 24, Appl
4	246.5	17.2	316	4	US-09-620-461-24	Sequence 24, Appl
5	245	17.1	340	4	US-09-651-200-2	Sequence 2, Appli
6	245	17.1	441	4	US-09-651-200-4	Sequence 4, Appli
7	245	17.1	534	4	US-09-651-200-6	Sequence 6, Appli
8	245	17.1	534	4	US-09-651-200-24	Sequence 24, Appl
9	238.5	16.7	315	4	US-09-910-174B-28	Sequence 28, Appl
10	238.5	16.7	315	4	US-09-620-461-28	Sequence 28, Appl
11	223	15.6	513	4	US-09-910-174B-18	Sequence 18, Appl
12	223	15.6	513	4	US-09-620-461-18	Sequence 18, Appl
13	217.5	15.2	540	2	US-08-724-394A-4	Sequence 4, Appli
14	215.5	15.1	731	4	US-09-910-174B-15	Sequence 15, Appl
15	215.5	15.1	731	4	US-09-620-461-15	Sequence 15, Appl
16	213.5	14.9	584	4	US-09-910-174B-16	Sequence 16, Appl
17	213.5	14.9	584	4	US-09-620-461-16	Sequence 16, Appl
18	212.5	14.8	610	2	US-08-724-394A-5	Sequence 5, Appli
19	211.5	14.8	526	4	US-09-910-174B-9	Sequence 9, Appli
20	211.5	14.8	526	4	US-09-620-461-9	Sequence 9, Appli
21	211.5	14.8	589	2	US-08-724-394A-1	Sequence 1, Appli
22	207.5	14.5	319	4	US-09-910-174B-12	Sequence 12, Appl
23	207.5	14.5	319	4	US-09-620-461-12	Sequence 12, Appl
24	207.5	14.5	342	2	US-08-724-394A-6	Sequence 6, Appli
25	207.5	14.5	357	4	US-09-910-174B-14	Sequence 14, Appl
26	207.5	14.5	357	4	US-09-620-461-14	Sequence 14, Appl
27	204	14.3	290	4	US-09-910-174B-19	Sequence 19, Appl
28	204	14.3	290	4	US-09-620-461-19	Sequence 19, Appl
29	204	14.3	350	4	US-09-651-200-25	Sequence 25, Appl
30	204	14.3	350	4	US-09-910-174B-17	Sequence 17, Appl
31	204	14.3	350	4	US-09-620-461-17	Sequence 17, Appl
32	199.5	13.9	290	4	US-09-910-174B-32	Sequence 32, Appl
33	196	13.7	296	4	US-09-667-135-36	Sequence 36, Appl
34	193	13.5	527	4	US-09-910-174B-10	Sequence 10, Appl
35	193	13.5	527	4	US-09-620-461-10	Sequence 10, Appl
36	192	13.4	329	4	US-09-651-200-18	Sequence 18, Appl
37	192	13.4	329	4	US-09-303-040-6	Sequence 6, Appli
38	188.5	13.2	290	4	US-09-910-174B-8	Sequence 8, Appli
39	188.5	13.2	290	4	US-09-620-461-8	Sequence 8, Appli
40	186	13.0	529	4	US-09-910-174B-13	Sequence 13, Appl
41	186	13.0	529	4	US-09-620-461-13	Sequence 13, Appl
42	186	13.0	581	2	US-08-724-394A-2	Sequence 2, Appli
43	179	12.5	523	4	US-09-910-174B-11	Sequence 11, Appl
44	179	12.5	523	4	US-09-620-461-11	Sequence 11, Appl
45	179	12.5	581	2	US-08-724-394A-3	Sequence 3, Appli

ALIGNMENTS

RESULT 1
US-09-404-879A-393
; Sequence 393, Application US/09404879A
; Patent No. 6468546
; GENERAL INFORMATION:
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: King, Gordon E.
; APPLICANT: Algate, Paul A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; TITLE OF INVENTION: DIAGNOSIS OF OVARIAN CANCER
; FILE REFERENCE: 210121.462C2
; CURRENT APPLICATION NUMBER: US/09/404,879A
; CURRENT FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 393
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 393
; LENGTH: 282
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-404-879A-393

Query Match 100.0%; Score 1431; DB 4; Length 282;
Best Local Similarity 100.0%; Pred. No. 2.8e-138;
Matches 282; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60

Qy         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
              ||||||||||||||||||||||||||||||||||||||||||
Db        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

RESULT 2
US-09-404-879A-392
; Sequence 392, Application US/09404879A
; Patent No. 6468546

```
; GENERAL INFORMATION:
;  APPLICANT:  Mitcham, Jennifer L.
;  APPLICANT:  King, Gordon E.
;  APPLICANT:  Algate, Paul A.
;  TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR THE THERAPY AND
;  TITLE OF INVENTION:  DIAGNOSIS OF OVARIAN CANCER
;  FILE REFERENCE:  210121.462C2
;  CURRENT APPLICATION NUMBER: US/09/404,879A
;  CURRENT FILING DATE:  1999-09-24
;  NUMBER OF SEQ ID NOS:  393
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 392
;   LENGTH: 309
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-404-879A-392

  Query Match             100.0%;  Score 1431;  DB 4;  Length 309;
  Best Local Similarity   100.0%;  Pred. No. 3.2e-138;
  Matches  282;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 87

Qy         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         88 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 147

Qy        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        148 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 207

Qy        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        208 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 267

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
              |||||||||||||||||||||||||||||||||||||||||||
Db        268 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 309


RESULT 3
US-09-910-174B-24
; Sequence 24, Application US/09910174B
; Patent No. 6630575
; GENERAL INFORMATION:
;  APPLICANT; Coyle, Anthony J.
;  APPLICANT:  Fraser, Christopher C.
;  APPLICANT:  Manning, Stephen
;  TITLE OF INVENTION: B7-H2 Molecules, No. 6630575el Members of the B7
;  TITLE OF INVENTION:  Family and Uses Thereof
;  FILE REFERENCE: 35800/236924
;  CURRENT APPLICATION NUMBER: US/09/910,174B
;  CURRENT FILING DATE:  2001-07-20
;  PRIOR APPLICATION NUMBER: US 09/620,461
;  PRIOR FILING DATE: 2000-07-20
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 316
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-910-174B-24

  Query Match             17.2%;  Score 246.5;  DB 4;  Length 316;
  Best Local Similarity   30.2%;  Pred. No. 7e-17;
  Matches   70;  Conservative   44;  Mismatches   99;  Indels   19;  Gaps    9;

Qy         21 GAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTF--EPDIKLSDIVIQWLKEGVLG 78
              ||    : | ::|   : |        :| |  | |:|  ||   |: : : |
Db         15 GAALGALWFCLTGALEVQVPEDPVVALVGTDATLCCSFSPEPGFSLAQLNLIWQLTDTKQ 74

Qy         79 LVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGK 138
              ||| | ||:|    |   :  |||:| | :  |||||||: |:: | |:: |: :: :
Db         75 LVHSFAEGQD----QGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCF-VSIRDF 129

Qy        139 GNANLEYKTGA-FSMPEVNVDYN-----ASSETLRCEAPRWFPQPTVVWASQVDQGANFS 192
              |:| :  :  | :| | : :: |       : |: | : | :|:  | |  |  ||   :
Db        130 GSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYRGYPEAEVFW--QDGQGVPLT 187

Qy        193 EVSNTSFELNSENVTMKVVSVLYNVT-INNTYSCMIENDIAK--ATGDIKVT 241
                 || :: :|    | |||   |   | ||||:: | : :  | | : :|
Db        188 GNVTTS-QMANEQGLFDVHSVLRVVLGANGTYSCLVRNPVLQQDAHGSVTIT 238


RESULT 4
US-09-620-461-24
; Sequence 24, Application US/09620461
; Patent No. 6635750
; GENERAL INFORMATION:
;  APPLICANT:  Coyle, Anthony J.
;  APPLICANT:  Fraser, Christopher C.
;  APPLICANT:  Manning, Stephen
;  TITLE OF INVENTION:  B7-H2 Molecules, No. 6635750el Members of the B7
;  TITLE OF INVENTION:  Family and Uses Thereof
;  FILE REFERENCE:  5800-149
;  CURRENT APPLICATION NUMBER: US/09/620,461
;  CURRENT FILING DATE:  2000-07-20
;  NUMBER OF SEQ ID NOS:  29
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 24
;   LENGTH: 316
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-620-461-24

  Query Match             17.2%;  Score 246.5;  DB 4;  Length 316;
  Best Local Similarity   30.2%;  Pred. No. 7e-17;
  Matches   70;  Conservative   44;  Mismatches   99;  Indels   19;  Gaps    9;

Qy         21 GAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTF--EPDIKLSDIVIQWLKEGVLG 78
              ||    : | ::|   : |        :| |  | |:|  ||   |: : : |
Db         15 GAALGALWFCLTGALEVQVPEDPVVALVGTDATLCCSFSPEPGFSLAQLNLIWQLTDTKQ 74

Qy         79 LVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGK 138
              ||| | ||:|    |   :  |||:| | :  |||||||: |:: | |:: |: :: :
Db         75 LVHSFAEGQD----QGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCF-VSIRDF 129

Qy        139 GNANLEYKTGA-FSMPEVNVDYN-----ASSETLRCEAPRWFPQPTVVWASQVDQGANFS 192
              |:| :  :  | :| | : :: |       : |: | : | :|:  | |  |  ||   :
Db        130 GSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYRGYPEAEVFW--QDGQGVPLT 187

Qy        193 EVSNTSFELNSENVTMKVVSVLYNVT-INNTYSCMIENDIAK--ATGDIKVT 241
                 || :: :|    | |||   |   | ||||:: | : :  | | : :|
Db        188 GNVTTS-QMANEQGLFDVHSVLRVVLGANGTYSCLVRNPVLQQDAHGSVTIT 238


RESULT 5
US-09-651-200-2
; Sequence 2, Application US/09651200
; Patent No. 6429303
; GENERAL INFORMATION:
;  APPLICANT:  Green et al
;  TITLE OF INVENTION:  Polynucleotides Encoding Members of the Human B
;  TITLE OF INVENTION:  Lymphocyte Activation Antigen B-7 Family and
;  TITLE OF INVENTION:  Polypeptides Encoded Thereby
;  FILE REFERENCE:  15966-562 (CURA-62)
;  CURRENT APPLICATION NUMBER: US/09/651,200
;  CURRENT FILING DATE:  2000-08-30
;  PRIOR APPLICATION NUMBER:  60/152383
;  PRIOR FILING DATE:  1999-09-03
;  PRIOR APPLICATION NUMBER:  60/172909
;  PRIOR FILING DATE:  1999-12-21
;  PRIOR APPLICATION NUMBER:  60/183578
;  PRIOR FILING DATE:  2000-02-18
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: May 30, 2004, 02:13:55 ; Search time 420 Seconds
(without alignments)
3054.262 Million cell updates/sec

Title: US-10-063-567-60
Perfect score: 1431
Sequence: 1 MASLGQILFWSIISIIIILA.....SSFFAISWALLPLSPYLMLK 282

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 2960401 seqs, 2274450654 residues

Total number of hits satisfying chosen parameters: 5920802

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+_p2n.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/US10063567/runat_28052004_132954_2021/app_query.fasta_1.455
-DB=Published_Applications_NA -QFMT=fastap -SUFFIX=rnpb -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100
-THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0
-MAXLEN=2000000000 -USER=US10063567_@CGN_1_1_723_@runat_28052004_132954_2021
-NCPU=6 -ICPU=3 -NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100
-LONGLOG -DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5
-FGAPOP=6 -FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : Published_Applications_NA:*
1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq:*
10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq:*
11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq:*
12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
13: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq2:*
14: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq:*
15: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq:*
16: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
17: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq:*
18: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
19: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1431	100.0	849	9	US-09-915-789A-6	Sequence 6, Appli
2	1431	100.0	1065	9	US-09-877-065-5	Sequence 5, Appli
3	1431	100.0	1658	9	US-09-989-722-290	Sequence 290, App
4	1431	100.0	1658	9	US-09-989-723-290	Sequence 290, App
5	1431	100.0	1658	9	US-09-989-279-290	Sequence 290, App
6	1431	100.0	1658	9	US-09-989-727-290	Sequence 290, App
7	1431	100.0	1658	9	US-09-989-731-290	Sequence 290, App
8	1431	100.0	1658	9	US-09-989-732-290	Sequence 290, App
9	1431	100.0	1658	9	US-09-991-073-290	Sequence 290, App
10	1431	100.0	1658	9	US-09-990-442-290	Sequence 290, App
11	1431	100.0	1658	9	US-09-991-163-290	Sequence 290, App
12	1431	100.0	1658	9	US-09-993-604-290	Sequence 290, App
13	1431	100.0	1658	9	US-09-990-456-290	Sequence 290, App
14	1431	100.0	1658	9	US-09-989-721-290	Sequence 290, App
15	1431	100.0	1658	9	US-09-992-598-290	Sequence 290, App
16	1431	100.0	1658	9	US-09-989-293A-290	Sequence 290, App
17	1431	100.0	1658	9	US-09-989-735-290	Sequence 290, App
18	1431	100.0	1658	9	US-09-990-444-290	Sequence 290, App
19	1431	100.0	1658	9	US-09-991-181-290	Sequence 290, App
20	1431	100.0	1658	9	US-09-989-730-290	Sequence 290, App
21	1431	100.0	1658	9	US-09-990-436-290	Sequence 290, App
22	1431	100.0	1658	9	US-09-993-687-290	Sequence 290, App
23	1431	100.0	1658	10	US-09-989-734-290	Sequence 290, App
24	1431	100.0	1658	10	US-09-997-653-290	Sequence 290, App
25	1431	100.0	1658	10	US-09-993-667-290	Sequence 290, App
26	1431	100.0	1658	10	US-09-997-428-290	Sequence 290, App
27	1431	100.0	1658	10	US-09-997-666-290	Sequence 290, App
28	1431	100.0	1658	10	US-09-990-438-290	Sequence 290, App
29	1431	100.0	1658	10	US-09-990-562-290	Sequence 290, App
30	1431	100.0	1658	10	US-09-990-711-290	Sequence 290, App
31	1431	100.0	1658	10	US-09-989-726-290	Sequence 290, App
32	1431	100.0	1658	10	US-09-998-156-290	Sequence 290, App
33	1431	100.0	1658	10	US-09-990-437-290	Sequence 290, App
34	1431	100.0	1658	10	US-09-991-157-290	Sequence 290, App
35	1431	100.0	1658	10	US-09-997-514-290	Sequence 290, App
36	1431	100.0	1658	10	US-09-997-573-290	Sequence 290, App
37	1431	100.0	1658	10	US-09-991-172-290	Sequence 290, App
38	1431	100.0	1658	10	US-09-990-726-290	Sequence 290, App
39	1431	100.0	1658	10	US-09-997-559-290	Sequence 290, App
40	1431	100.0	1658	10	US-09-997-601-290	Sequence 290, App
41	1431	100.0	1658	10	US-09-990-443-290	Sequence 290, App
42	1431	100.0	1658	10	US-09-929-769-4	Sequence 4, Appli
43	1431	100.0	1658	10	US-09-991-854-290	Sequence 290, App
44	1431	100.0	1658	10	US-09-997-628-290	Sequence 290, App
45	1431	100.0	1658	10	US-09-997-683-290	Sequence 290, App

ALIGNMENTS

RESULT 1
US-09-915-789A-6
; Sequence 6, Application US/09915789A
; Patent No. US20020168762A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Lieping
; TITLE OF INVENTION: B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY
; TITLE OF INVENTION: MOLECULES
; FILE REFERENCE: 07039-219001
; CURRENT APPLICATION NUMBER: US/09/915,789A
; CURRENT FILING DATE: 2002-06-04
; PRIOR APPLICATION NUMBER: US 60/220,991
; PRIOR FILING DATE: 2000-07-27
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 849
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-915-789A-6

Alignment Scores:
Pred. No.: 1.7e-172 Length: 849

Score:	1431.00	Matches:	282
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	9	Gaps:	0

US-10-063-567-60 (1-282) x US-09-915-789A-6 (1-849)

```
Qy          1 MetAlaSerLeuGlyGlnIleLeuPheTrpSerIleIleSerIleIleIleIleLeuAla 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 ATGGCTTCCCTGGGGCAGATCCTCTTCTGGAGCATAATTAGCATCATCATTATTCTGGCT 60

Qy         21 GlyAlaIleAlaLeuIleIleGlyPheGlyIleSerGlyArgHisSerIleThrValThr 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAGGGAGACACTCCATCACAGTCACT 120

Qy         41 ThrValAlaSerAlaGlyAsnIleGlyGluAspGlyIleLeuSerCysThrPheGluPro 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 ACTGTCGCCTCAGCTGGGAACATTGGGGAGGATGGAATCCTGAGCTGCACTTTTGAACCT 180

Qy         61 AspIleLysLeuSerAspIleValIleGlnTrpLeuLysGluGlyValLeuGlyLeuVal 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GACATCAAACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTGGTC 240

Qy         81 HisGluPheLysGluGlyLysAspGluLeuSerGluGlnAspGluMetPheArgGlyArg 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 CATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAATGTTCAGAGGCCGG 300

Qy        101 ThrAlaValPheAlaAspGlnValIleValGlyAsnAlaSerLeuArgLeuLysAsnVal 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 ACAGCAGTGTTTGCTGATCAAGTGATAGTTGGCAATGCCTCTTTGCGGCTGAAAAACGTG 360

Qy        121 GlnLeuThrAspAlaGlyThrTyrLysCysTyrIleIleThrSerLysGlyLysGlyAsn 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CAACTCACAGATGCTGGCACCTACAAATGTTATATCATCACTTCTAAAGGCAAGGGGAAT 420

Qy        141 AlaAsnLeuGluTyrLysThrGlyAlaPheSerMetProGluValAsnValAspTyrAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 GCTAACCTTGAGTATAAAACTGGAGCCTTCAGCATGCCGGAAGTGAATGTGGACTATAAT 480

Qy        161 AlaSerSerGluThrLeuArgCysGluAlaProArgTrpPheProGlnProThrValVal 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 GCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCCAGCCCACAGTGGTC 540

Qy        181 TrpAlaSerGlnValAspGlnGlyAlaAsnPheSerGluValSerAsnThrSerPheGlu 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 TGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAATACCAGCTTTGAG 600

Qy        201 LeuAsnSerGluAsnValThrMetLysValValSerValLeuTyrAsnValThrIleAsn 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 CTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTGTGCTCTACAATGTTACGATCAAC 660

Qy        221 AsnThrTyrSerCysMetIleGluAsnAspIleAlaLysAlaThrGlyAspIleLysVal 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AACACATACTCCTGTATGATTGAAAATGACATTGCCAAAGCAACAGGGGATATCAAAGTG 720

Qy        241 ThrGluSerGluIleLysArgArgSerHisLeuGlnLeuLeuAsnSerLysAlaSerLeu 260
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 ACAGAATCGGAGATCAAAAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTG 780

Qy        261 CysValSerSerPhePheAlaIleSerTrpAlaLeuLeuProLeuSerProTyrLeuMet 280
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TGTGTCTCTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTGATG 840

Qy        281 LeuLys 282
              ||||||
Db        841 CTAAAA 846
```

RESULT 2
US-09-877-065-5
; Sequence 5, Application US/09877065
; Patent No. US20020051990A1
; GENERAL INFORMATION:
; APPLICANT: OPLE, ERIC
; APPLICANT: MCLACHLAN, KAREN
; APPLICANT: HEARD, CHERYL J.
; TITLE OF INVENTION: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR
; TITLE OF INVENTION: TREATMENT AND DIAGNOSIS OF OVARIAN CARCINOMAS
; FILE REFERENCE: 037003-0280631
; CURRENT APPLICATION NUMBER: US/09/877,065
; CURRENT FILING DATE: 2001-06-11
; PRIOR APPLICATION NUMBER: 60/210,451
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 1065
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-877-065-5

Alignment Scores:			
Pred. No.:	2.46e-172	Length:	1065
Score:	1431.00	Matches:	282
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	9	Gaps:	0

US-10-063-567-60 (1-282) x US-09-877-065-5 (1-1065)

```
Qy          1 MetAlaSerLeuGlyGlnIleLeuPheTrpSerIleIleSerIleIleIleIleLeuAla 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         72 ATGGCTTCCCTGGGGCAGATCCTCTTCTGGAGCATAATTAGCATCATCATTATTCTGGCT 131

Qy         21 GlyAlaIleAlaLeuIleIleGlyPheGlyIleSerGlyArgHisSerIleThrValThr 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        132 GGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAGGGAGACACTCCATCACAGTCACT 191

Qy         41 ThrValAlaSerAlaGlyAsnIleGlyGluAspGlyIleLeuSerCysThrPheGluPro 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        192 ACTGTCGCCTCAGCTGGGAACATTGGGGAGGATGGAATCCTGAGCTGCACTTTTGAACCT 251

Qy         61 AspIleLysLeuSerAspIleValIleGlnTrpLeuLysGluGlyValLeuGlyLeuVal 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        252 GACATCAAACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTGGTC 311

Qy         81 HisGluPheLysGluGlyLysAspGluLeuSerGluGlnAspGluMetPheArgGlyArg 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        312 CATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAATGTTCAGAGGCCGG 371

Qy        101 ThrAlaValPheAlaAspGlnValIleValGlyAsnAlaSerLeuArgLeuLysAsnVal 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        372 ACAGCAGTGTTTGCTGATCAAGTGATAGTTGGCAATGCCTCTTTGCGGCTGAAAAACGTG 431

Qy        121 GlnLeuThrAspAlaGlyThrTyrLysCysTyrIleIleThrSerLysGlyLysGlyAsn 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        432 CAACTCACAGATGCTGGCACCTACAAATGTTATATCATCACTTCTAAAGGCAAGGGGAAT 491

Qy        141 AlaAsnLeuGluTyrLysThrGlyAlaPheSerMetProGluValAsnValAspTyrAsn 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        492 GCTAACCTTGAGTATAAAACTGGAGCCTTCAGCATGCCGGAAGTGAATGTGGACTATAAT 551

Qy        161 AlaSerSerGluThrLeuArgCysGluAlaProArgTrpPheProGlnProThrValVal 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        552 GCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCCAGCCCACAGTGGTC 611

Qy        181 TrpAlaSerGlnValAspGlnGlyAlaAsnPheSerGluValSerAsnThrSerPheGlu 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        612 TGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAATACCAGCTTTGAG 671

Qy        201 LeuAsnSerGluAsnValThrMetLysValValSerValLeuTyrAsnValThrIleAsn 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        672 CTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTGTGCTCTACAATGTTACGATCAAC 731

Qy        221 AsnThrTyrSerCysMetIleGluAsnAspIleAlaLysAlaThrGlyAspIleLysVal 240
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        732 AACACATACTCCTGTATGATTGAAAATGACATTGCCAAAGCAACAGGGGATATCAAAGTG 791

Qy        241 ThrGluSerGluIleLysArgArgSerHisLeuGlnLeuLeuAsnSerLysAlaSerLeu 260
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        792 ACAGAATCGGAGATCAAAAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTG 851

Qy        261 CysValSerSerPhePheAlaIleSerTrpAlaLeuLeuProLeuSerProTyrLeuMet 280
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        852 TGTGTCTCTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTGATG 911

Qy        281 LeuLys 282
                ||||||
Db        912 CTAAAA 917

RESULT 3
US-09-989-722-290
; Sequence 290, Application US/09989722
; Patent No. US20020072067A1
; GENERAL INFORMATION:
;  APPLICANT: Ashkenazi,Avi J.
;  APPLICANT:  Baker,Kevin P.
;  APPLICANT:  Botstein,David
;  APPLICANT:  Desnoyers,Luc
;  APPLICANT:  Eaton,Dan L.
;  APPLICANT:  Ferrara,Napoleone
;  APPLICANT:  Fong,Sherman
;  APPLICANT:  Gerber,Hanspeter
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,J.Christopher
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Kljavin,Ivar J.
;  APPLICANT:  Napier,Mary A.
;  APPLICANT:  Pan,James
;  APPLICANT:  Paoni,Nicholas F.
;  APPLICANT:  Roy, Margaret Ann
;  APPLICANT:  Stewart, Timothy A.
;  APPLICANT:  Tumas, Daniel
;  APPLICANT:  Watanabe, Colin K.
;  APPLICANT:  Williams, P. Mickey
;  APPLICANT:  Wood, William I.
;  APPLICANT:  Zhang, Zemin
;  TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;  TITLE OF INVENTION:  Acids Encoding the Same
;  FILE REFERENCE: P2730P1C63
;  CURRENT APPLICATION NUMBER: US/09/989,722
;  CURRENT FILING DATE:  2001-11-19
;  PRIOR APPLICATION NUMBER: 60/049787
;  PRIOR FILING DATE: 1997-06-16
;  PRIOR APPLICATION NUMBER: 60/062250
;  PRIOR FILING DATE: 1997-10-17
;  PRIOR APPLICATION NUMBER: 60/065186
;  PRIOR FILING DATE: 1997-11-12
;  PRIOR APPLICATION NUMBER: 60/065311
;  PRIOR FILING DATE: 1997-11-13
;  PRIOR APPLICATION NUMBER: 60/066770
;  PRIOR FILING DATE: 1997-11-24
;  PRIOR APPLICATION NUMBER: 60/075945
;  PRIOR FILING DATE: 1998-02-25
;  PRIOR APPLICATION NUMBER: 60/078910
;  PRIOR FILING DATE: 1998-03-20
;  PRIOR APPLICATION NUMBER: 60/083322
;  PRIOR FILING DATE: 1998-04-28
;  PRIOR APPLICATION NUMBER: 60/084600
;  PRIOR FILING DATE: 1998-05-07
;  PRIOR APPLICATION NUMBER: 60/087106
;  PRIOR FILING DATE: 1998-05-28
;  PRIOR APPLICATION NUMBER: 60/087607
;  PRIOR FILING DATE: 1998-06-02
;  PRIOR APPLICATION NUMBER: 60/087609
;  PRIOR FILING DATE: 1998-06-02
;  PRIOR APPLICATION NUMBER: 60/087759
;  PRIOR FILING DATE: 1998-06-02
;  PRIOR APPLICATION NUMBER: 60/087827
;  PRIOR FILING DATE: 1998-06-03
;  PRIOR APPLICATION NUMBER: 60/088021
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088025
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088026
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088028
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088029
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088030
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088033
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088326
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/088167
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/088202
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/088212
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/088217
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/088655
;  PRIOR FILING DATE: 1998-06-09
;  PRIOR APPLICATION NUMBER: 60/088734
;  PRIOR FILING DATE: 1998-06-10
;  PRIOR APPLICATION NUMBER: 60/088738
;  PRIOR FILING DATE: 1998-06-10
;  PRIOR APPLICATION NUMBER: 60/088742
;  PRIOR FILING DATE: 1998-06-10
;  PRIOR APPLICATION NUMBER: 60/088810
;  PRIOR FILING DATE: 1998-06-10
;  PRIOR APPLICATION NUMBER: 60/088824
;  PRIOR FILING DATE: 1998-06-10
;  PRIOR APPLICATION NUMBER: 60/088826
;  PRIOR FILING DATE: 1998-06-10
;  PRIOR APPLICATION NUMBER: 60/088858
;  PRIOR FILING DATE: 1998-06-11
;  PRIOR APPLICATION NUMBER: 60/088861
;  PRIOR FILING DATE: 1998-06-11
;  PRIOR APPLICATION NUMBER: 60/088876
;  PRIOR FILING DATE: 1998-06-11
;  PRIOR APPLICATION NUMBER: 60/089105
;  PRIOR FILING DATE: 1998-06-12
;  PRIOR APPLICATION NUMBER: 60/089440
;  PRIOR FILING DATE: 1998-06-16
;  PRIOR APPLICATION NUMBER: 60/089512
;  PRIOR FILING DATE: 1998-06-16
;  PRIOR APPLICATION NUMBER: 60/089514
;  PRIOR FILING DATE: 1998-06-16
;  PRIOR APPLICATION NUMBER: 60/089532
;  PRIOR FILING DATE: 1998-06-17
;  PRIOR APPLICATION NUMBER: 60/089538
;  PRIOR FILING DATE: 1998-06-17
;  PRIOR APPLICATION NUMBER: 60/089598
;  PRIOR FILING DATE: 1998-06-17
;  PRIOR APPLICATION NUMBER: 60/089599
;  PRIOR FILING DATE: 1998-06-17
;  PRIOR APPLICATION NUMBER: 60/089600
;  PRIOR FILING DATE: 1998-06-17
;  PRIOR APPLICATION NUMBER: 60/089653
;  PRIOR FILING DATE: 1998-06-17
;  PRIOR APPLICATION NUMBER: 60/089801
;  PRIOR FILING DATE: 1998-06-18
;  PRIOR APPLICATION NUMBER: 60/089907
;  PRIOR FILING DATE: 1998-06-18
;  PRIOR APPLICATION NUMBER: 60/089908
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 29, 2004, 22:45:14 ; Search time 149 Seconds
(without alignments)
6175.225 Million cell updates/sec

Title: US-10-063-567-59
Perfect score: 1658
Sequence: 1 ggaaggcagcggcagctcca.....aaaaaaaaaaaaaaaaaaaa 1658

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/2/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/2/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/2/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/2/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/2/ina/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata/2/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	1609.8	97.1	2627	4	US-09-404-879A-391	Sequence 391, App
	2	589.8	35.6	1567	4	US-09-404-879A-74	Sequence 74, Appl
	3	589.8	35.6	1567	4	US-09-338-933-74	Sequence 74, Appl
	4	589.8	35.6	1567	4	US-09-215-681-74	Sequence 74, Appl
	5	589.8	35.6	1567	4	US-09-216-003A-74	Sequence 74, Appl
	6	530.6	32.0	541	4	US-09-404-879A-28	Sequence 28, Appl
	7	530.6	32.0	541	4	US-09-338-933-28	Sequence 28, Appl
	8	530.6	32.0	541	4	US-09-215-681-28	Sequence 28, Appl
	9	530.6	32.0	541	4	US-09-216-003A-28	Sequence 28, Appl
	10	69	4.2	332	4	US-09-621-976-16031	Sequence 16031, A
c	11	67.6	4.1	396	4	US-09-640-173-10	Sequence 10, Appl
c	12	67.6	4.1	396	4	US-09-713-550-10	Sequence 10, Appl
	13	67	4.0	2790	3	US-08-800-291B-1	Sequence 1, Appli
	14	66.6	4.0	413	4	US-09-227-357-71	Sequence 71, Appl
	15	66.2	4.0	329	4	US-09-621-976-16012	Sequence 16012, A
	16	66.2	4.0	332	4	US-09-621-976-16050	Sequence 16050, A
	17	66.2	4.0	332	4	US-09-621-976-16053	Sequence 16053, A
	18	66.2	4.0	333	4	US-09-621-976-16032	Sequence 16032, A
	19	66.2	4.0	333	4	US-09-621-976-16045	Sequence 16045, A
	20	66.2	4.0	334	4	US-09-621-976-16044	Sequence 16044, A
	21	66.2	4.0	335	4	US-09-621-976-16061	Sequence 16061, A
	22	66.2	4.0	336	4	US-09-621-976-16013	Sequence 16013, A
	23	66.2	4.0	338	4	US-09-621-976-16041	Sequence 16041, A
	24	66.2	4.0	347	4	US-09-621-976-16026	Sequence 16026, A
	25	66.2	4.0	357	4	US-09-621-976-16058	Sequence 16058, A
	26	66.2	4.0	359	4	US-09-621-976-16008	Sequence 16008, A
	27	66.2	4.0	359	4	US-09-621-976-16019	Sequence 16019, A
	28	66.2	4.0	362	4	US-09-621-976-16010	Sequence 16010, A
	29	66.2	4.0	365	4	US-09-621-976-16042	Sequence 16042, A
	30	66.2	4.0	1582	3	US-08-545-196B-10	Sequence 10, Appl
	31	66.2	4.0	1582	3	US-08-545-196B-12	Sequence 12, Appl
	32	66	4.0	299	4	US-09-621-976-10211	Sequence 10211, A
	33	65.8	4.0	326	4	US-09-621-976-16024	Sequence 16024, A
	34	65.6	4.0	2567	3	US-08-993-260-4	Sequence 4, Appli
	35	65.4	3.9	371	4	US-09-621-976-16048	Sequence 16048, A
	36	65	3.9	327	4	US-09-621-976-16018	Sequence 16018, A
	37	65	3.9	339	4	US-09-621-976-16015	Sequence 16015, A
	38	64.8	3.9	1736	3	US-09-182-816-22	Sequence 22, Appl
c	39	64.8	3.9	1736	3	US-09-182-816-24	Sequence 24, Appl
	40	64.8	3.9	1736	3	US-09-471-528-22	Sequence 22, Appl
c	41	64.8	3.9	1736	3	US-09-471-528-24	Sequence 24, Appl
	42	64.8	3.9	1736	3	US-09-634-530-22	Sequence 22, Appl
c	43	64.8	3.9	1736	3	US-09-634-530-24	Sequence 24, Appl
	44	64.6	3.9	336	4	US-09-621-976-16051	Sequence 16051, A
	45	64.6	3.9	1474	3	US-08-821-994-64	Sequence 64, Appl

ALIGNMENTS

RESULT 1
US-09-404-879A-391
; Sequence 391, Application US/09404879A
; Patent No. 6468546
; GENERAL INFORMATION:
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: King, Gordon E.
; APPLICANT: Algate, Paul A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; TITLE OF INVENTION: DIAGNOSIS OF OVARIAN CANCER
; FILE REFERENCE: 210121.462C2
; CURRENT APPLICATION NUMBER: US/09/404,879A
; CURRENT FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 393
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 391
; LENGTH: 2627
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-404-879A-391

Query Match 97.1%; Score 1609.8; DB 4; Length 2627;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1611; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy          1 GGAAGGCAGCGGCAGCTCCACTCAGCCAGTACCCAGATACGCTGGGAACCTTCCCCAGCC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         23 GGAAGGCAGCGGCAGCTCCACTCAGCCAGTACCCAGATACGCTGGGAACCTTCCCCAGCC 82

Qy         61 ATGGCTTCCCTGGGGCAGATCCTCTTCTGGAGCATAATTAGCATCATCATTATTCTGGCT 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         83 ATGGCTTCCCTGGGGCAGATCCTCTTCTGGAGCATAATTAGCATCATCATTATTCTGGCT 142

Qy        121 GGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAGGGAGACACTCCATCACAGTCACT 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        143 GGAGCAATTGCACTCATCATTGGCTTTGGTATTTCAGGGAGACACTCCATCACAGTCACT 202

Qy        181 ACTGTCGCCTCAGCTGGGAACATTGGGGAGGATGGAATCCTGAGCTGCACTTTTGAACCT 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        203 ACTGTCGCCTCAGCTGGGAACATTGGGGAGGATGGAATCCTGAGCTGCACTTTTGAACCT 262

Qy        241 GACATCAAACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTGGTC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        263 GACATCAAACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTGGTC 322

Qy        301 CATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAATGTTCAGAGGCCGG 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        323 CATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAATGTTCAGAGGCCGG 382

Qy        361 ACAGCAGTGTTTGCTGATCAAGTGATAGTTGGCAATGCCTCTTTGCGGCTGAAAAACGTG 420
```

```
Db        383 ACAGCAGTGTTTGCTGATCAAGTGATAGTTGGCAATGCCTCTTTGCGGCTGAAAAACGTG 442
Qy        421 CAACTCACAGATGCTGGCACCTACAAATGTTATATCATCACTTCTAAAGGCAAGGGGAAT 480
Db        443 CAACTCACAGATGCTGGCACCTACAAATGTTATATCATCACTTCTAAAGGCAAGGGGAAT 502
Qy        481 GCTAACCTTGAGTATAAAACTGGAGCCTTCAGCATGCCGGAAGTGAATGTGGACTATAAT 540
Db        503 GCTAACCTTGAGTATAAAACTGGAGCCTTCAGCATGCCGGAAGTGAATGTGGACTATAAT 562
Qy        541 GCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCCAGCCCACAGTGGTC 600
Db        563 GCCAGCTCAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCCAGCCCACAGTGGTC 622
Qy        601 TGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAATACCAGCTTTGAG 660
Db        623 TGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAATACCAGCTTTGAG 682
Qy        661 CTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTGTGCTCTACAATGTTACGATCAAC 720
Db        683 CTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTGTGCTCTACAATGTTACGATCAAC 742
Qy        721 AACACATACTCCTGTATGATTGAAAATGACATTGCCAAAGCAACAGGGGATATCAAAGTG 780
Db        743 AACACATACTCCTGTATGATTGAAAATGACATTGCCAAAGCAACAGGGGATATCAAAGTG 802
Qy        781 ACAGAATCGGAGATCAAAAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTG 840
Db        803 ACAGAATCGGAGATCAAAAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTG 862
Qy        841 TGTGTCTCTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTGATG 900
Db        863 TGTGTCTCTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTGATG 922
Qy        901 CTAAAATAATGTGCCTTGGCCACAAAAAAGCATGCAAAGTCATTGTTACAACAGGGATCT 960
Db        923 CTAAAATAATGTGCCTTGGCCACAAAAAAGCATGCAAAGTCATTGTTACAACAGGGATCT 982
Qy        961 ACAGAACTATTTCACCACCAGATATGACCTAGTTTTATATTTCTGGGAGGAAATGAATTC 1020
Db        983 ACAGAACTATTTCACCACCAGATATGACCTAGTTTTATATTTCTGGGAGGAAATGAATTC 1042
Qy       1021 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 1080
Db       1043 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 1102
Qy       1081 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 1140
Db       1103 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 1162
Qy       1141 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 1200
Db       1163 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 1222
Qy       1201 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 1260
Db       1223 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 1282
Qy       1261 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 1320
Db       1283 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 1342
Qy       1321 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 1380
Db       1343 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 1402
Qy       1381 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 1440
Db       1403 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 1462
Qy       1441 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 1500
Db       1463 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 1522
Qy       1501 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 1560
Db       1523 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 1582
Qy       1561 CGGGGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAAAAAA 1613
Db       1583 CGGCGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAACAAA 1635
```

RESULT 2
US-09-404-879A-74
; Sequence 74, Application US/09404879A
; Patent No. 6468546
; GENERAL INFORMATION:
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: King, Gordon E.
; APPLICANT: Algate, Paul A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; TITLE OF INVENTION: DIAGNOSIS OF OVARIAN CANCER
; FILE REFERENCE: 210121.462C2
; CURRENT APPLICATION NUMBER: US/09/404,879A
; CURRENT FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 393
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 74
; LENGTH: 1567
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-404-879A-74

Query Match 35.6%; Score 589.8; DB 4; Length 1567;
Best Local Similarity 99.7%; Pred. No. 2.9e-139;
Matches 591; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1021 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 1080
Db          1 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 60
Qy       1081 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 1140
Db         61 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 120
Qy       1141 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 1200
Db        121 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 180
Qy       1201 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 1260
Db        181 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 240
Qy       1261 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 1320
Db        241 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 300
Qy       1321 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 1380
Db        301 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 360
Qy       1381 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 1440
Db        361 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 420
Qy       1441 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 1500
Db        421 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 480
Qy       1501 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 1560
Db        481 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 540
```

```
                ||| |||||||||||||||||||||||||||||||||||||||||||||||||| |||
Db        541 CGGCGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAACAAA 593


RESULT 3
US-09-338-933-74
; Sequence 74, Application US/09338933
; Patent No. 6488931
; GENERAL INFORMATION:
;  APPLICANT: Mitcham, Jennifer Lynn
;  APPLICANT: King, Gordon E.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY OF
;  TITLE OF INVENTION: OVARIAN CANCER
;  FILE REFERENCE: 210121.462C1
;  CURRENT APPLICATION NUMBER: US/09/338,933
;  CURRENT FILING DATE: 1999-06-23
;  NUMBER OF SEQ ID NOS: 312
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 74
;   LENGTH: 1567
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-09-338-933-74

  Query Match             35.6%;  Score 589.8;  DB 4;  Length 1567;
  Best Local Similarity   99.7%;  Pred. No. 2.9e-139;
  Matches  591;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1021 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 60

Qy       1081 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 120

Qy       1141 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 1200
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 180

Qy       1201 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 1260
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 240

Qy       1261 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 1320
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 300

Qy       1321 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 1380
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 360

Qy       1381 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 1440
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 420

Qy       1441 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 1500
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 480

Qy       1501 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 1560
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 540

Qy       1561 CGGGGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAAAAAA 1613
             ||| |||||||||||||||||||||||||||||||||||||||||||||||| |||
Db        541 CGGCGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAACAAA 593


RESULT 4
US-09-215-681-74
; Sequence 74, Application US/09215681A
; Patent No. 6528253
; GENERAL INFORMATION:
;  APPLICANT: Mitcham, Jennifer L.
;  APPLICANT: Frudakis, Tony N.
;  APPLICANT: King, Gordon E.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSIS
;  TITLE OF INVENTION: OF OVARIAN CANCER
;  FILE REFERENCE: 210121.463
;  CURRENT APPLICATION NUMBER: US/09/215,681A
;  CURRENT FILING DATE: 1998-12-17
;  NUMBER OF SEQ ID NOS: 310
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 74
;   LENGTH: 1567
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-09-215-681-74

  Query Match             35.6%;  Score 589.8;  DB 4;  Length 1567;
  Best Local Similarity   99.7%;  Pred. No. 2.9e-139;
  Matches  591;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1021 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 ATATCTAGAAGTCTGGAGTGAGCAAACAAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGA 60

Qy       1081 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGGCTCCAATATGAACAAGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATA 120

Qy       1141 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 1200
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 ATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGCACGTGGAGACAAGT 180

Qy       1201 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 1260
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGTGAGAGGACAGGAT 240

Qy       1261 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 1320
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAATGTTGCTCTGAGGAA 300

Qy       1321 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 1380
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 GCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACAAATTAAGCTGTAGT 360

Qy       1381 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 1440
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 ATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTT 420

Qy       1441 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 1500
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 AGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTCTTC 480

Qy       1501 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 1560
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 CCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGCATAAACAGAGCAGT 540

Qy       1561 CGGGGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAAAAAA 1613
             ||| |||||||||||||||||||||||||||||||||||||||||||||||| |||
Db        541 CGGCGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTTAAACAAACAAA 593


RESULT 5
US-09-216-003A-74
; Sequence 74, Application US/09216003A
; Patent No. 6670463
; GENERAL INFORMATION:
;  APPLICANT:  Mitcham, Jennifer L.
;  APPLICANT:  Frudakis, Tony N.
;  APPLICANT:  King, Gordon E.
;  TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR THERAPY OF OVARIAN CANCER
;  FILE REFERENCE:  210121.462
```

```
Qy          61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy         121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy         181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy         241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
               |||||||||||||||||||||||||||||||||||||||||
Db         241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

RESULT 2
AAB12557
ID AAB12557 standard; protein; 282 AA.
XX
AC AAB12557;
XX
DT 07-NOV-2000 (first entry)
XX
DE Human ovarian carcinoma antigen O8E protein SEQ ID NO:393.
XX
KW Human; ovarian carcinoma; ovarian cancer; therapy; diagnosis;
KW tumour antigen; identification; cytostatic; gene therapy; vaccine.
XX
OS Homo sapiens.
XX
PN WO200036107-A2.
XX
PD 22-JUN-2000.
XX
PF 17-DEC-1999; 99WO-US030270.
XX
PR 17-DEC-1998; 98US-00215681.
PR 17-DEC-1998; 98US-00216003.
PR 23-JUN-1999; 99US-00338933.
PR 24-SEP-1999; 99US-00404879.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, King GE, Algate PA, Frudakis TN;
XX
DR WPI; 2000-431589/37.
XX
PT Immunogenic portion of an ovarian carcinoma protein and the nucleic acid
PT encoding it, useful for the diagnosis, prevention and treatment of
PT cancer, preferably ovarian cancer.
XX
PS Example 2; Page 207; 299pp; English.
XX
CC The present invention describes an isolated polypeptide comprising an
CC immunogenic portion of an ovarian carcinoma protein (or its variants).
CC Ovarian carcinoma proteins, and polynucleotides encoding them, have
CC cytostatic activity and can be used in gene therapy and vaccines. Ovarian
CC carcinoma polypeptides, nucleic acids, antibodies and vaccines are useful
CC for the prevention, diagnosis and treatment of cancer, preferably ovarian
CC cancer. AAA69691 to AAA70077 and AAB12552 to AAB12557 represent human
CC ovarian carcinoma polynucleotides and proteins used in the
CC exemplification of the present invention
XX
SQ Sequence 282 AA;

Query Match 100.0%; Score 1431; DB 3; Length 282;
Best Local Similarity 100.0%; Pred. No. 3.9e-118;
Matches 282; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60

Qy         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
               |||||||||||||||||||||||||||||||||||||||||
Db        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

RESULT 3
AAU29132
ID AAU29132 standard; protein; 282 AA.
XX
AC AAU29132;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human PRO polypeptide sequence #109.
XX
KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200168848-A2.
XX
PD 20-SEP-2001.
XX
PF 28-FEB-2001; 2001WO-US006520.
XX
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 06-MAR-2000; 2000US-0186968P.
PR 14-MAR-2000; 2000US-0189320P.
PR 14-MAR-2000; 2000US-0189328P.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000US-0190828P.
PR 21-MAR-2000; 2000US-0191007P.
PR 21-MAR-2000; 2000US-0191048P.
PR 21-MAR-2000; 2000US-0191314P.
PR 28-MAR-2000; 2000US-0192655P.
PR 29-MAR-2000; 2000US-0193032P.
PR 29-MAR-2000; 2000US-0193053P.
PR 30-MAR-2000; 2000WO-US008439.
PR 04-APR-2000; 2000US-0194449P.
PR 04-APR-2000; 2000US-0194647P.
PR 11-APR-2000; 2000US-0195975P.
PR 11-APR-2000; 2000US-0196000P.
PR 11-APR-2000; 2000US-0196187P.
PR 11-APR-2000; 2000US-0196690P.
PR 11-APR-2000; 2000US-0196820P.
PR 18-APR-2000; 2000US-0198121P.
PR 18-APR-2000; 2000US-0198585P.
PR 25-APR-2000; 2000US-0199397P.
PR 25-APR-2000; 2000US-0199550P.
PR 25-APR-2000; 2000US-0199654P.
PR 03-MAY-2000; 2000US-0201516P.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
                ||||||||||||||||||||||||||||||||||||||||||
Db        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282


RESULT 5
AAB99204
ID   AAB99204 standard; protein; 282 AA.
XX
AC   AAB99204;
XX
DT   04-SEP-2001  (first entry)
XX
DE   Human ovarian tumour-derived antigen O8E #1.
XX
KW   Cytostatic; human; breast tumour protein; breast cancer; ovarian tumour;
KW   antigen; O8E.
XX
OS   Homo sapiens.
XX
PN   WO200140269-A2.
XX
PD   07-JUN-2001.
XX
PF   29-NOV-2000; 2000WO-US032520.
XX
PR   30-NOV-1999;   99US-00451651.
PR   22-FEB-2000; 2000US-00510662.
PR   10-MAR-2000; 2000US-00523586.
PR   07-APR-2000; 2000US-00545068.
PR   15-MAY-2000; 2000US-00571025.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Dillon DC,  Day CH,  Jiang Y,  Houghton RL,  Mitcham JL,  Wang A;
XX
DR   WPI; 2001-356154/37.
DR   N-PSDB; AAH55681.
XX
PT   Breast tumor polypeptides and the nucleic acids that encode them, useful
PT   for the prevention, diagnosis and treatment of breast cancer.
XX
PS   Example 3; Page 190; 221pp; English.
XX
CC   The present invention relates to human breast tumour protein coding
CC   sequences (see AAH55479-AAH55513, AAH55517-AAH55679 and AAH55682-
CC   AAH55762). The breast tumour protein DNA sequences may be used in the
CC   prevention, diagnosis and treatment of diseases associated with
CC   inappropriate expression of the breast tumour protein e.g. breast cancer.
CC   The present sequence is a human ovarian tumour-derived antigen, which was
CC   used in an example from the present invention
XX
SQ   Sequence 282 AA;

  Query Match             100.0%;  Score 1431;  DB 4;  Length 282;
  Best Local Similarity   100.0%;  Pred. No. 3.9e-118;
  Matches  282;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60

Qy         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
              ||||||||||||||||||||||||||||||||||||||||||
Db        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282


RESULT 6
AAB65242
ID   AAB65242 standard; protein; 282 AA.
XX
AC   AAB65242;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO1291 (UNQ659) protein sequence SEQ ID NO:291.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic; cell death;
KW   cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US008439.
XX
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2001-032160/04.
DR   N-PSDB; AAF44205.
XX
PT   PRO polynucleotides used to produce polypeptides used to target bioactive
PT   molecules such as toxins, radiolabels or antibodies, to specific cells,
PT   to cause targeted cell death.
XX
PS   Claim 12; Fig 208; 935pp; English.
XX
```

```
Qy          61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy         121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy         181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy         241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
               |||||||||||||||||||||||||||||||||||||||||
Db         241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

RESULT 13
ABB76274
ID ABB76274 standard; protein; 282 AA.
XX
AC ABB76274;
XX
DT 12-AUG-2002 (first entry)
XX
DE Breast BS265 polypeptide.
XX
KW BS265; human; breast; cancer; tumour; metastasis; diagnosis;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2002034749-A1.
XX
PD 21-MAR-2002.
XX
PF 07-MAY-2001; 2001US-00850178.
XX
PR 18-NOV-1997; 97US-00972376.
PR 18-NOV-1998; 98US-00193944.
XX
PA (BILL/) BILLINGEL P A.
PA (COHE/) COHEN M.
PA (COLP/) COLPITTS T L.
PA (FRIE/) FRIEDMAN P N.
PA (GORD/) GORDON J.
PA (GRAN/) GRANADOS E N.
PA (HODG/) HODGES S C.
PA (KLAS/) KLASS M R.
PA (KRAT/) KRATOCHVIL J D.
PA (ROBE/) ROBERTS-RAPP L A.
PA (RUSS/) RUSSELL J C.
PA (STRO/) STROUPE S D.
XX
PI Billingel PA, Cohen M, Colpitts TL, Friedman PN, Gordon J;
PI Granados EN, Hodges SC, Klass MR, Kratochvil JD, Roberts-Rapp LA;
PI Russell JC, Stroupe SD;
XX
DR WPI; 2002-403712/43.
DR N-PSDB; ABL57354.
XX
PT New BS265 proteins and nucleic acids, useful for detecting, diagnosing,
PT staging, monitoring, prognosticating, in vivo imaging, preventing,
PT treating, or determining the predisposition of an individual to breast
PT cancer.
XX
PS Claim 54; Page 45-46; 52pp; English.
XX
CC The present sequence is the protein sequence of human breast BS265
CC protein, as predicted from a BS265 expressed sequence tag clone (see
CC ABL57354). The invention provides a set of contiguous and partially
CC overlapping cDNA sequences (see ABL57345-63), designated as BS265 and
CC transcribed from breast tissue, and the polypeptides encoded by them.
CC These are useful for detecting, diagnosing, staging, monitoring,
CC prognosticating, in vivo imaging, preventing, treating, or determining
CC the predisposition of an individual to diseases and conditions of the
CC breast, such as breast cancer. Also provided are antibodies which
CC specifically bind to BS265 proteins, and agonists or inhibitors which
CC prevent action of the proteins, and which are useful for treatment of
CC breast disease, especially tumours and metastases
XX
SQ Sequence 282 AA;

```
  Query Match             100.0%;  Score 1431;  DB 5;  Length 282;
  Best Local Similarity   100.0%;  Pred. No. 3.9e-118;
  Matches  282;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60

Qy          61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy         121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy         181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy         241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
               |||||||||||||||||||||||||||||||||||||||||
Db         241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

RESULT 14
AAE18336
ID AAE18336 standard; protein; 282 AA.
XX
AC AAE18336;
XX
DT 07-MAY-2002 (first entry)
XX
DE Human B7-like protein (B7-L).
XX
KW Human; B7-like protein; B7-L; reproductive disorder; autoimmune disease;
KW proliferative disorder; infertility; hyperplasia; cancer; lung; breast;
KW brain; seminal vesicle; haematopoietic system; tumour; diabetes mellitus;
KW rheumatoid arthritis; systemic lupus erythematosis; toxic shock syndrome;
KW inflammatory bowel disease; psoriasis; allergy; Crohn's disease; vaccine;
KW Grave's disease; arteriosclerosis; multiple sclerosis; hypersensitivity;
KW nephropathy; skin disorder; endocrinopathy; vasculopathy; gynaecological;
KW myasthenia ravis; anaemia; lymphoproliferative disorder; neuroprotective;
KW cytostatic; multiple myeloma; tissue-degenerating disease; nephrotropic;
KW immunosuppressive; asthma; virucide; gene therapy.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1. .24
FT /label= Signal_peptide
FT Protein 25. .282
FT /label= Human_mature_B7-L_protein
XX
PN WO200202624-A2.
XX
PD 10-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-US021297.
XX
PR 30-JUN-2000; 2000US-0215645P.
XX

```
PA   (AMGE-) AMGEN INC.
XX
PI   Fox M,  Sullivan JK,  Fang M;
XX
DR   WPI; 2002-171639/22.
DR   N-PSDB; AAD29253.
XX
PT   Novel B7-like polypeptides, polynucleotides and their modulators useful
PT   for prevention and treatment of reproductive, immune and proliferative
PT   disorders, e.g. cancer, arteriosclerosis.
XX
PS   Claim 13; Fig 1A-1B; 133pp; English.
XX
CC   The present invention relates to an isolated B7-like (B7-L) polypeptide
CC   and its polynucleotide. B7-1 and its modulators are useful for treating
CC   reproductive disorders (e.g. infertility, miscarriage, preterm labour and
CC   delivery and endometriosis) and proliferative disorders. Antibodies,
CC   soluble proteins comprising extracellular domains and other regulators of
CC   B7-L are useful for enhancing the immune response to tumours. B7-1 plays
CC   a role in growth and maintenance of cancer cells based on the observation
CC   of seminal vesicle hyperplasia in transgenic mice overexpressing B7-1.
CC   Modulators of B7-1 are useful for the treatment of cancer e.g. seminal
CC   vesicle, lung, brain, breast, ovarian, testicular cancer and cancers of
CC   haematopoietic system. B7-1 and their modulators are useful to treat
CC   autoimmune diseases such as systemic lupus erythematosis, rheumatoid
CC   arthritis, immune thrombocytopenic purpura and psoriasis, chronic
CC   inflammatory disease such as inflammatory bowel disease (Crohn's disease
CC   and ulcerative colitis), Grave's disease, Hashimoto's thyroiditis and
CC   diabetes mellitus. They are also useful as immunosuppressive agents for
CC   bone marrow and organ transplantation or to prolong graft survival.
CC   Modulators of B7-L are also useful for diagnosis and treatment of
CC   diseases involving abnormal cell proliferation, arteriosclerosis and
CC   vascular restenosis. Soluble B7-L serves as vaccine adjuvants.
CC   Antagonists of B7-L are useful for alleviation of toxic shock syndrome or
CC   allosensitisation due to blood transfusions, and for treatment of
CC   multiple sclerosis, allergy, asthma and hypersensitivity reactions,
CC   nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and
CC   pemphigoid), endocrinopathies, various pneumopathies, vasculopathies,
CC   coeliac disease, anaemia, thromobocytopaenia, Guillain-Barre syndrome and
CC   myasthenia gravis, and lymphoproliferative disorders such as multiple
CC   myeloma. B7-L gene is useful in gene therapy and to map the locations of
CC   B7-L gene and related genes on chromosomes, as hybridisation probes in
CC   diagnostic assays, for isolating corresponding chromosomal B7-L genes,
CC   and to identify heritable tissue-degenerating diseases. The present
CC   sequence is human B7-L protein
XX
SQ   Sequence 282 AA;

  Query Match             100.0%;  Score 1431;  DB 5;  Length 282;
  Best Local Similarity   100.0%;  Pred. No. 3.9e-118;
  Matches  282;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60

Qy         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
              |||||||||||||||||||||||||||||||||||||||||||
Db        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

```
RESULT 15
ABB09879
ID   ABB09879 standard; protein; 282 AA.
XX
AC   ABB09879;
XX
DT   30-JUL-2002  (first entry)
XX
DE   Amino acid sequence of the OREO gene (gene B).
XX
KW   Human; gene A; ovarian tumour; gene B; OREO; ovarian cancer.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          12. .31
FT                   /note= "predicted transmembrane domain"
FT   Domain          46. .145
FT                   /note= "predicted Ig domain"
FT   Modified-site   112
FT                   /note= "N-glycosylation site"
FT   Modified-site   160
FT                   /note= "N-glycosylation site"
FT   Modified-site   190
FT                   /note= "N-glycosylation site"
FT   Modified-site   196
FT                   /note= "N-glycosylation site"
FT   Modified-site   205
FT                   /note= "N-glycosylation site"
FT   Modified-site   216
FT                   /note= "N-glycosylation site"
FT   Modified-site   220
FT                   /note= "N-glycosylation site"
XX
PN   WO200194641-A2.
XX
PD   13-DEC-2001.
XX
PF   11-JUN-2001; 2001WO-US018700.
XX
PR   09-JUN-2000; 2000US-0210451P.
XX
PA   (IDEC-) IDEC PHARM CORP.
XX
PI   Ople E,  Mclachlan K,  Heard C;
XX
DR   WPI; 2002-404365/43.
DR   N-PSDB; ABL56582.
XX
PT   New polynucleotide and corresponding antigens from human ovarian cancer
PT   cells, useful for treatment and diagnosis of ovarian cancer.
XX
PS   Claim 12; Fig 7b; 71pp; English.
XX
CC   The present sequence represents a protein designated OREO. The OREO (Ople
CC   RDA of Epithelial Tissue vs. Ovary tumour) gene is a novel gene, also
CC   designated gene B. This gene was identified by representational
CC   difference analysis (RDA) screening, and is selectively expressed by
CC   certain human ovarian tumours. The specification also describes gene A,
CC   identified by the same method. Gene A and B polynucleotides are useful
CC   for detecting ovarian cancer. Their polypeptides are useful for treating
CC   ovarian cancer
XX
SQ   Sequence 282 AA;

  Query Match             100.0%;  Score 1431;  DB 5;  Length 282;
  Best Local Similarity   100.0%;  Pred. No. 3.9e-118;
  Matches  282;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP 60
```

```
Qy         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV 120

Qy        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV 180

Qy        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV 240

Qy        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
              |||||||||||||||||||||||||||||||||||||||||||
Db        241 TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK 282
```

Search completed: May 28, 2004, 14:34:07
Job time : 62 secs